Treating children with inflammatory bowel disease: Current and new perspectives
| Autor: | Graziella Guariso, Marco Gasparetto |
|---|---|
| Přispěvatelé: | Gasparetto, Marco [0000-0002-3882-3606], Apollo - University of Cambridge Repository |
| Rok vydání: | 2017 |
| Předmět: |
Crohn’s disease
medicine.medical_specialty Biologic Monitoring Diet therapy Disease Inflammatory bowel disease 03 medical and health sciences Paediatric inflammatory bowel disease 0302 clinical medicine Crohn Disease Medicine Humans 030212 general & internal medicine Intensive care medicine Child Biosimilar Pharmaceuticals Immunosuppressant Immunosuppression Therapy Crohn's disease Biological Products Clinical Trials as Topic business.industry Gastroenterology Age Factors Minireviews General Medicine Biomarker Fecal Microbiota Transplantation medicine.disease Ulcerative colitis Gastrointestinal Microbiome Clinical trial Treatment Systematic review Treatment Outcome Biomarker (medicine) 030211 gastroenterology & hepatology Colitis Ulcerative Therapy business Immunosuppressive Agents Diet Therapy |
| Zdroj: | World Journal of Gastroenterology |
| Popis: | Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gut characterised by alternating periods of remission and relapse. Whilst the mechanism underlying this disease is yet to be fully understood, old and newer generation treatments can only target selected pathways of this complex inflammatory process. This narrative review aims to provide an update on the most recent advances in treatment of paediatric IBD. A MEDLINE search was conducted using “paediatric inflammatory bowel disease”, “paediatric Crohn’s disease”, “paediatric ulcerative colitis”, “treatment”, “therapy”, “immunosuppressant”, “biologic”, “monitoring” and “biomarkers” as key words. Clinical trials, systematic reviews, and meta-analyses published between 2014 and 2016 were selected. Studies referring to earlier periods were also considered in case the data was relevant to our scope. Major advances have been achieved in monitoring the individual metabolism, toxicity and response to relevant medications in IBD including thiopurines and biologics. New biologics acting on novel mechanisms such as selective interference with lymphocyte trafficking are emerging treatment options. Current research is investing in the development of reliable prognostic biomarkers, aiming to move towards personalised treatments targeted to individual patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|